Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cyclo Therapeutics Inc.

    NASDAQ: CYTH · Real-Time Price · USD
    0.72
    -0.00 (-0.08%)
    At close: Mar 25, 2025, 3:59 PM

    Cyclo Therapeutics Statistics

    Share Statistics

    Cyclo Therapeutics has 32.74M shares outstanding. The number of shares has increased by 14.4% in one year.

    Shares Outstanding

    n/a
    		 32.74M

    Shares Change (YoY)

    n/a
    		 14.4%

    Shares Change (QoQ)

    n/a
    		 13.79%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 274

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 434.13K, so 1.33% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 434.13K

    Short % of Shares Out

    n/a
    		 1.33%

    Short % of Float

    n/a
    		 1.51%

    Short Ratio (days to cover)

    n/a
    		 7.26

    Valuation Ratios

    The PE ratio is -1.29 and the forward PE ratio is -5.54. Cyclo Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -1.29

    Forward PE

    n/a
    		 -5.54

    PS Ratio

    n/a
    		 24.12

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 5.46

    P/FCF Ratio

    n/a
    		 -1.6

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cyclo Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.22.

    Current Ratio

    n/a
    		 1.45

    Quick Ratio

    n/a
    		 1.42

    Debt / Equity

    n/a
    		 0.22

    Debt / EBITDA

    n/a
    		 -0.05

    Debt / FCF

    n/a
    		 -0.06

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $134,550.62

    Profits Per Employee

    n/a
    		 $-2,507,162.75

    Employee Count

    n/a
    		 8

    Asset Turnover

    n/a
    		 0.08

    Inventory Turnover

    n/a
    		 0.39

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -44.62% in the last 52 weeks. The beta is -0.57, so Cyclo Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.57

    52-Week Price Change

    n/a
    		 -44.62%

    50-Day Moving Average

    n/a
    		 0.79

    200-Day Moving Average

    n/a
    		 0.85

    Relative Strength Index (RSI)

    n/a
    		 47.9

    Average Volume (20 Days)

    n/a
    		 1,761,627

    Income Statement

    In the last 12 months, Cyclo Therapeutics had revenue of 1.08M and earned -20.06M in profits. Earnings per share was -1.23.

    Revenue

    n/a
    		 1.08M

    Gross Profit

    n/a
    		 977.95K

    Operating Income

    n/a
    		 -20.05M

    Net Income

    n/a
    		 -20.06M

    EBITDA

    n/a
    		 -20.03M

    EBIT

    n/a
    		 -20.05M

    Earnings Per Share (EPS)

    n/a
    		 -1.23
    Full Income Statement

    Balance Sheet

    The company has 9.25M in cash and 1.03M in debt, giving a net cash position of 8.21M.

    Cash & Cash Equivalents

    n/a
    		 9.25M

    Total Debt

    n/a
    		 1.03M

    Net Cash

    n/a
    		 8.21M

    Retained Earnings

    n/a
    		 -83.86M

    Total Assets

    n/a
    		 5.25M

    Working Capital

    n/a
    		 -15.46M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -16.19M and capital expenditures -2.42K, giving a free cash flow of -16.19M.

    Operating Cash Flow

    n/a
    		 -16.19M

    Capital Expenditures

    n/a
    		 -2.42K

    Free Cash Flow

    n/a
    		 -16.19M

    FCF Per Share

    n/a
    		 -0.99
    Full Cash Flow Statement

    Margins

    Gross margin is 90.85%, with operating and profit margins of -1862.69% and -1863.36%.

    Gross Margin

    n/a
    		 90.85%

    Operating Margin

    n/a
    		 -1862.69%

    Pretax Margin

    n/a
    		 -1863.36%

    Profit Margin

    n/a
    		 -1863.36%

    EBITDA Margin

    n/a
    		 -1860.9%

    EBIT Margin

    n/a
    		 -1862.69%

    FCF Margin

    n/a
    		 -1503.84%

    Dividends & Yields

    CYTH does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CYTH is $0.95, which is 31.9% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $0.95

    Price Target Difference

    n/a
    		 31.9%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 9, 2020. It was a backward split with a ratio of 1:100.

    Last Split Date

    n/a
    		 Dec 9, 2020

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:100

    Scores

    Altman Z-Score

    n/a
    		 -45.56

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist